Teng Yulu, Yang Zhenzhen, Peng Yiwei, Yang Yiliang, Chen Siyu, Li Jiajia, Gao Datong, Sun Wen, Wu Zinan, Zhou Yanxia, Li Xinru, Qi Xianrong
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Drug Clinical Trial Center, Peking University Third Hospital, Peking University, Beijing, 100191, China.
Adv Healthc Mater. 2025 Jan;14(1):e2401851. doi: 10.1002/adhm.202401851. Epub 2024 Oct 24.
Dying tumor cells regulated by immunogenic cell death (ICD) inducers are promising candidates for cancer vaccine development because of their comprehensive antigen spectrum. However, their limited immunogenicity and potential tumorigenicity hinder clinical translation. To address these challenges, a nano-orchestrator is developed that targets the endoplasmic reticulum (ER) stress, a critical pre-ICD event, to optimize the "precise dose" of ER stress. Using a clinical-range irradiation fluence (50‒200 J cm) with an 808 nm laser, the release of damage associated molecular patterns (DAMPs) and antigens are precisely regulated. A fluence of 150 J cm (2 W cm for 75 s) increases dendritic cell maturation and antitumor T cell proliferation, providing valuable clinical insights. The ER stress nano-orchestrator enhances both adjuvanticity and antigenicity via the protein kinase R-like endoplasmic reticulum kinase (PERK)-C/EBP homologous protein (CHOP) pathway to regulate ICD-induced DAMPs and promote tumor cell apoptosis. These optimized ER stress phototherapeutic dying tumor cells can serve as prophylactic vaccines, achieving a remarkable 100% success rate against tumor rechallenge in vivo. Additionally, the nano-orchestrator shows the potential to develop in situ therapeutic tumor vaccines when combined with anti-PD-L1 treatment, providing important insights into enhancing the efficacy of immune checkpoint regulators by modulating endogenous immune responses.
由免疫原性细胞死亡(ICD)诱导剂调控的垂死肿瘤细胞因其全面的抗原谱而有望成为癌症疫苗开发的候选对象。然而,其有限的免疫原性和潜在的致瘤性阻碍了临床转化。为应对这些挑战,研发了一种纳米协调器,其靶向内质网(ER)应激这一关键的ICD前期事件,以优化ER应激的“精确剂量”。使用808 nm激光的临床范围照射通量(50‒200 J/cm²),可精确调控损伤相关分子模式(DAMP)和抗原的释放。150 J/cm²(2 W/cm²持续75秒)的通量可增加树突状细胞成熟和抗肿瘤T细胞增殖,提供了有价值的临床见解。ER应激纳米协调器通过蛋白激酶R样内质网激酶(PERK)-C/EBP同源蛋白(CHOP)途径增强佐剂性和抗原性,以调节ICD诱导的DAMP并促进肿瘤细胞凋亡。这些经过优化的ER应激光疗垂死肿瘤细胞可作为预防性疫苗,在体内对肿瘤再激发的成功率达到了显著的100%。此外,该纳米协调器与抗PD-L1治疗联合使用时显示出开发原位治疗性肿瘤疫苗的潜力,为通过调节内源性免疫反应提高免疫检查点调节剂的疗效提供了重要见解。